Etravirine: A novel nonnucleoside reverse transcriptase inhibitor for managing human immunodeficiency virus infection

American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists
Raghda K Elsayed, David J Caldwell

Abstract

The pharmacology, efficacy, and safety of etravirine and its clinical utility with respect to the available alternative human immunodeficiency virus (HIV) treatment options are reviewed. While single mutations confer resistance to earlier nonnucleoside reverse transcriptase inhibitors (NNRTIs), etravirine exhibited an increased barrier to resistance by requiring multiple mutations for resistance to occur in preclinical studies. Randomized controlled trials have demonstrated the efficacy of etravirine in achieving HIV RNA viral loads of <50 copies/ mL and a significant increase in baseline CD4+ lymphocyte count in treatment-experienced patients. There has been a trend toward increased rates of death, progression to acquired immunodeficiency syndrome, and opportunistic infections in patients using placebo during Phase III trials. Baseline patient characteristics that correlate with changes in etravirine efficacy are reported. Mild-to-moderate rash and nausea are the most common adverse effects of etravirine. If rash is suspected, etravirine should be discontinued and rechallenge should be avoided due to the risk of severe and possibly fatal skin reactions. Unlike some antiretrovirals, increased risks of hepatic, lipid, or neurops...Continue Reading

References

Jan 19, 1991·Lancet·C KatlamaM Gentilini
Mar 1, 1991·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·C Katlama
Jun 1, 1997·Genitourinary Medicine·C Katlama
Dec 12, 2003·The New England Journal of Medicine·Gregory K RobbinsUNKNOWN AIDS Clinical Trials Group 384 Team
Jul 26, 2006·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Mohamed G AttaDerek M Fine
Nov 14, 2006·PLoS Pathogens·Anna FigueiredoGilda Tachedjian
Dec 7, 2006·American Journal of Pharmaceutical Education·Martin M Zdanowicz
Mar 7, 2007·Health Affairs·Perri Klass
Jul 10, 2007·Lancet·Bernard Hirschel, Thomas Perneger
Jan 8, 2008·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Jennifer CocohobaRuth M Greenblatt
May 1, 2008·The Annals of Pharmacotherapy·Monika PeetersGoedele De Smedt
May 16, 2008·The New England Journal of Medicine·Sharon A RiddlerUNKNOWN AIDS Clinical Trials Group Study A5142 Team
May 22, 2008·British Journal of Clinical Pharmacology·Monika Schöller-GyüreRichard M W Hoetelmans
Jun 14, 2008·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Martin S HirschDouglas D Richman
Jul 26, 2008·The Journal of Antimicrobial Chemotherapy·J M LlibreB Clotet
Aug 5, 2008·JAMA : the Journal of the American Medical Association·Scott M HammerUNKNOWN International AIDS Society-USA
Sep 4, 2008·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Julio MontanerUNKNOWN TMC125-C203 Study Group
Nov 1, 2008·Drugs·Emma D Deeks, Gillian M Keating
Apr 3, 2009·Enfermedades infecciosas y microbiología clínica·Jose Maria Gatell
Apr 18, 2009·Current Opinion in HIV and AIDS·Thomas N Kakuda, Monika Schöller-Gyüre
Oct 10, 2009·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Y YazdanpanahUNKNOWN ANRS 139 TRIO Trial Group
Nov 17, 2009·Journal of Emergency Nursing : JEN : Official Publication of the Emergency Department Nurses Association·Patrice Callagy, Michelle Woodfall

❮ Previous
Next ❯

Citations

Dec 16, 2011·HIV Therapy·Jordan E Lake, Judith S Currier
Apr 20, 2011·Expert Opinion on Drug Metabolism & Toxicology·Mona Arab-AlameddineChantal Csajka
Jan 1, 2014·Journal of Clinical Pharmacy and Therapeutics·E Calvo-CidonchaR Morillo-Verdugo
Nov 18, 2020·Current Opinion in Pharmacology·Murugesan VanangamudiVigneshwaran Namasivayam
Dec 6, 2018·Journal of Medicinal Chemistry·Vigneshwaran NamasivayamSiddappa N Byrareddy

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Related Papers

Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
Carine CouzigouDaniel Vittecoq
Expert Opinion on Pharmacotherapy
Dushyantha S JayaweeraJose Castro
American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists
Vi T DoPatricia Pecora Fulco
© 2021 Meta ULC. All rights reserved